vs
GYRE THERAPEUTICS, INC.（GYRE）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是GYRE THERAPEUTICS, INC.的1.4倍（$50.3M vs $37.2M），GYRE THERAPEUTICS, INC.净利率更高（-3.7% vs -5.1%，领先1.4%），GYRE THERAPEUTICS, INC.同比增速更快（33.4% vs -14.2%），READING INTERNATIONAL INC自由现金流更多（$4.1M vs $-5.8M），过去两年GYRE THERAPEUTICS, INC.的营收复合增速更高（17.0% vs 5.6%）
GYRE Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性血液系统恶性肿瘤和实体瘤的新型靶向疗法，聚焦精准肿瘤学领域以满足未被满足的患者医疗需求，主要在北美地区开展业务。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
GYRE vs RDI — 直观对比
营收规模更大
RDI
是对方的1.4倍
$37.2M
营收增速更快
GYRE
高出47.6%
-14.2%
净利率更高
GYRE
高出1.4%
-5.1%
自由现金流更多
RDI
多$9.9M
$-5.8M
两年增速更快
GYRE
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.2M | $50.3M |
| 净利润 | $-1.4M | $-2.6M |
| 毛利率 | 95.3% | — |
| 营业利润率 | 0.3% | -1.9% |
| 净利率 | -3.7% | -5.1% |
| 营收同比 | 33.4% | -14.2% |
| 净利润同比 | -340.1% | -14.5% |
| 每股收益（稀释后） | $-0.01 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GYRERDI
| Q4 25 | $37.2M | $50.3M | ||
| Q3 25 | $30.6M | $52.2M | ||
| Q2 25 | $26.8M | $60.4M | ||
| Q1 25 | $22.1M | $40.2M | ||
| Q4 24 | $27.9M | $58.6M | ||
| Q3 24 | $25.5M | $60.1M | ||
| Q2 24 | $25.2M | $46.8M | ||
| Q1 24 | $27.2M | $45.1M |
净利润GYRERDI
| Q4 25 | $-1.4M | $-2.6M | ||
| Q3 25 | $5.9M | $-4.2M | ||
| Q2 25 | $1.6M | $-2.7M | ||
| Q1 25 | $3.7M | $-4.8M | ||
| Q4 24 | $569.0K | $-2.2M | ||
| Q3 24 | $2.9M | $-7.0M | ||
| Q2 24 | $4.5M | $-12.8M | ||
| Q1 24 | $9.9M | $-13.2M |
毛利率GYRERDI
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
营业利润率GYRERDI
| Q4 25 | 0.3% | -1.9% | ||
| Q3 25 | 22.7% | -0.6% | ||
| Q2 25 | 8.1% | 4.8% | ||
| Q1 25 | 10.3% | -17.2% | ||
| Q4 24 | 2.4% | 2.6% | ||
| Q3 24 | 16.6% | -0.6% | ||
| Q2 24 | 12.7% | -16.4% | ||
| Q1 24 | 29.7% | -16.7% |
净利率GYRERDI
| Q4 25 | -3.7% | -5.1% | ||
| Q3 25 | 19.4% | -8.0% | ||
| Q2 25 | 5.9% | -4.4% | ||
| Q1 25 | 16.9% | -11.8% | ||
| Q4 24 | 2.0% | -3.8% | ||
| Q3 24 | 11.2% | -11.7% | ||
| Q2 24 | 18.0% | -27.4% | ||
| Q1 24 | 36.6% | -29.4% |
每股收益（稀释后）GYRERDI
| Q4 25 | $-0.01 | $-0.11 | ||
| Q3 25 | $0.03 | $-0.18 | ||
| Q2 25 | $0.00 | $-0.12 | ||
| Q1 25 | $0.00 | $-0.21 | ||
| Q4 24 | $0.00 | $-0.11 | ||
| Q3 24 | $0.01 | $-0.31 | ||
| Q2 24 | $0.01 | $-0.57 | ||
| Q1 24 | $0.03 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $52.4M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $106.0M | $-18.2M |
| 总资产 | $166.1M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GYRERDI
| Q4 25 | $52.4M | $10.5M | ||
| Q3 25 | $60.0M | $8.1M | ||
| Q2 25 | $54.4M | $9.1M | ||
| Q1 25 | $29.9M | $5.9M | ||
| Q4 24 | $26.7M | $12.4M | ||
| Q3 24 | $25.1M | $10.1M | ||
| Q2 24 | $25.1M | $9.3M | ||
| Q1 24 | $37.4M | $7.5M |
总债务GYRERDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GYRERDI
| Q4 25 | $106.0M | $-18.2M | ||
| Q3 25 | $101.9M | $-12.1M | ||
| Q2 25 | $92.0M | $-7.7M | ||
| Q1 25 | $68.1M | $-8.1M | ||
| Q4 24 | $63.3M | $-4.4M | ||
| Q3 24 | $63.2M | $1.6M | ||
| Q2 24 | $60.4M | $6.5M | ||
| Q1 24 | $56.6M | $18.0M |
总资产GYRERDI
| Q4 25 | $166.1M | $434.9M | ||
| Q3 25 | $159.4M | $435.2M | ||
| Q2 25 | $152.6M | $438.1M | ||
| Q1 25 | $129.8M | $441.0M | ||
| Q4 24 | $125.4M | $471.0M | ||
| Q3 24 | $125.2M | $495.7M | ||
| Q2 24 | $120.9M | $494.9M | ||
| Q1 24 | $122.0M | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.6M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $-5.8M | $4.1M |
| 自由现金流率自由现金流/营收 | -15.5% | 8.2% |
| 资本支出强度资本支出/营收 | 0.4% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-180.0K | $-2.9M |
8季度趋势，按日历期对齐
经营现金流GYRERDI
| Q4 25 | $-5.6M | $4.3M | ||
| Q3 25 | $4.7M | $295.0K | ||
| Q2 25 | $2.1M | $1.6M | ||
| Q1 25 | $-129.0K | $-7.7M | ||
| Q4 24 | $-2.8M | $8.0M | ||
| Q3 24 | $1.7M | $1.3M | ||
| Q2 24 | $-5.5M | $-10.4M | ||
| Q1 24 | $2.9M | $-2.8M |
自由现金流GYRERDI
| Q4 25 | $-5.8M | $4.1M | ||
| Q3 25 | $4.0M | $-246.0K | ||
| Q2 25 | $1.8M | $1.2M | ||
| Q1 25 | $-251.0K | $-8.0M | ||
| Q4 24 | $-2.8M | $7.0M | ||
| Q3 24 | $1.0M | $-1.1M | ||
| Q2 24 | $-6.9M | $-10.6M | ||
| Q1 24 | $2.7M | $-4.7M |
自由现金流率GYRERDI
| Q4 25 | -15.5% | 8.2% | ||
| Q3 25 | 13.1% | -0.5% | ||
| Q2 25 | 6.8% | 1.9% | ||
| Q1 25 | -1.1% | -19.8% | ||
| Q4 24 | -10.1% | 12.0% | ||
| Q3 24 | 4.1% | -1.8% | ||
| Q2 24 | -27.5% | -22.7% | ||
| Q1 24 | 9.8% | -10.4% |
资本支出强度GYRERDI
| Q4 25 | 0.4% | 0.3% | ||
| Q3 25 | 2.2% | 1.0% | ||
| Q2 25 | 1.0% | 0.6% | ||
| Q1 25 | 0.6% | 0.6% | ||
| Q4 24 | 0.2% | 1.7% | ||
| Q3 24 | 2.7% | 4.0% | ||
| Q2 24 | 5.8% | 0.5% | ||
| Q1 24 | 0.9% | 4.3% |
现金转化率GYRERDI
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | -1.21× | — | ||
| Q1 24 | 0.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GYRE
暂无分部数据
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
